폴라리스AI파마

041910KOSDAQ

61.0 / 100

Reference Date: 2026-10-23

Financial Score26.5 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly up 1.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Polaris AI Pharma primarily operates in API (Active Pharmaceutical Ingredient) and CDMO (Contract Development and Manufacturing Organization) sectors, with API contributing 96.3% of its 2025 revenue. The company focuses on expanding high-value CDMO services while maintaining strong collaborations with domestic and international pharmaceutical firms, particularly emphasizing exports to the demanding Japanese market.

Number of Employees

167people

Average Salary

51.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.13Industry Average 15.005.0Point

In line with industry avg

PBR

0.55Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

4.66Industry Average 8.002.5Point

Below industry avg

Debt Ratio

22.92Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼7.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲807.7% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.7% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 5,630Won52-week high 8,92052-week low 4,300

1-month return3.0Point

1m 1.81% (flat)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0